Literature DB >> 11212234

Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.

A Ho1, S R Schwarze, S J Mermelstein, G Waksman, S F Dowdy.   

Abstract

The protein transduction domain (PTD) embedded in the HIV TAT protein (amino acids 47-57) has been shown to successfully mediate the introduction of heterologous peptides and proteins in excess of Mr 100,000 into mammalian cells in vitro and in vivo. We report here that the modeled structure of the TAT PTD is a strong amphipathic helix. On the basis of this information, we synthesized a series of synthetic PTDs that strengthen the alpha-helical content and optimize the placement of arginine residues. Several PTD peptides possessed significantly enhanced protein transduction potential compared with TAT in vitro and in vivo. These optimized PTDs have the potential to deliver both existing and novel anticancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212234

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  109 in total

1.  Evaluation of strategies for the intracellular delivery of proteins.

Authors:  Dongjiu Ye; Dong Xu; Alex U Singer; R L Juliano
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 2.  Development of mitochondrial gene replacement therapy.

Authors:  Shaharyar M Khan; James P Bennett
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

3.  Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting.

Authors:  Vijaya Gopal; Kunchur Guruprasad
Journal:  Syst Synth Biol       Date:  2011-02-17

4.  Rac1 recruits the adapter protein CMS/CD2AP to cell-cell contacts.

Authors:  Trynette J van Duijn; Eloise C Anthony; Paul J Hensbergen; André M Deelder; Peter L Hordijk
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

5.  Characterization of the cell-penetrating properties of the Epstein-Barr virus ZEBRA trans-activator.

Authors:  Romy Rothe; Lavinia Liguori; Ana Villegas-Mendez; Bruno Marques; Didier Grunwald; Emmanuel Drouet; Jean-Luc Lenormand
Journal:  J Biol Chem       Date:  2010-04-09       Impact factor: 5.157

6.  A novel human derived cell-penetrating peptide in drug delivery.

Authors:  Jian Zhao; Peng Gao; Wei Xiao; Li-Qiang Fan; Fu-Jun Wang; Su-Xia Li; Jian-Wen Liu
Journal:  Mol Biol Rep       Date:  2010-11-16       Impact factor: 2.316

7.  Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity.

Authors:  Ying Shen; William Yu; John G Hay; Harald Sauthoff
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

8.  p21-activated kinase (Pak) regulates NADPH oxidase activation in human neutrophils.

Authors:  Kendra D Martyn; Moon-Ju Kim; Mark T Quinn; Mary C Dinauer; Ulla G Knaus
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

9.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

10.  The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures.

Authors:  Bruno P Meloni; Amanda J Craig; Nadia Milech; Richard M Hopkins; Paul M Watt; Neville W Knuckey
Journal:  Cell Mol Neurobiol       Date:  2013-11-09       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.